文献速递妇科

子宫内膜异位症女性卵巢癌预后:一项32,419名女性的全国性回顾性队列研究

Ovarian cancer prognosis in women with endometriosis: a retrospective nationwide cohort study of 32,419 women.
PubMed 文献 · Am J Obstet Gynecol · 2020-08-22

该研究基于荷兰全国癌症登记与病理登记数据库,纳入1990至2015年确诊的32,419例卵巢癌女性,其中1,979例(6.1%)有组织学证实的子宫内膜异位症。调整混杂因素后,合并子宫内膜异位症者的总生存期仍优于无子宫内膜异位症者(调整后风险比0.89,95%置信区间0.83-0.95,P<.05)。

要点

  • 卵巢癌合并组织学证实的子宫内膜异位症者总生存期更长,粗风险比0.46(95%置信区间0.43-0.49,P<.0005)。
  • 调整混杂因素后,合并子宫内膜异位症者死亡风险仍较低,调整后风险比0.89(95%置信区间0.83-0.95,P<.05)。
  • 81.2%的卵巢癌合并子宫内膜异位症者为同步诊断,中位诊断年龄53岁(四分位距46-62)。

核心结论

  • 有组织学证实子宫内膜异位症的卵巢癌女性总生存期长于无子宫内膜异位症者,调整混杂因素后仍如此。
  • 作者认为未来卵巢癌治疗与预后研究应按子宫内膜异位症状态分层,并应向卵巢癌合并子宫内膜异位症患者解释子宫内膜异位症在卵巢癌生存中的作用。

研究设计与样本

  • 荷兰全国性回顾性队列研究,数据来自荷兰癌症登记库(1990至2015年确诊的卵巢癌女性)并链接荷兰全国组织病理学与细胞病理学登记库(Pathologisch-Anatomisch Landelijk Geautomatiseerd Archief)。
  • 共纳入32,419例卵巢癌患者,其中1,979例(6.1%)有组织学证实的子宫内膜异位症;比较两组预后,主要结局为总生存期,并按卵巢癌组织学亚型和分期进行亚组分析。
  • 采用多变量Cox比例风险分析估计风险比及95%置信区间,将两组间分布不同的变量作为混杂因素纳入多变量模型。

主要发现

  • 组织学诊断子宫内膜异位症的中位年龄为53岁(四分位距46-62)。
  • 全部卵巢癌合并子宫内膜异位症女性中,81.2%为同步诊断子宫内膜异位症与卵巢癌。
  • 子宫内膜异位症队列在卵巢癌诊断时更年轻、肿瘤特征更有利、更常接受卵巢癌手术治疗。
  • 粗分析中,有组织学证实子宫内膜异位症者预后显著更好:风险比0.46(95%置信区间0.43-0.49,P<.0005)。
  • 调整混杂因素后,有组织学证实子宫内膜异位症者预后仍显著更好:调整后风险比0.89(95%置信区间0.83-0.95,P<.05)。

临床怎么用

  • 原文结论指出,未来关于卵巢癌治疗与预后的研究应考虑按子宫内膜异位症状态分层,以阐明其作用。
  • 原文结论指出,应向诊断为卵巢癌合并子宫内膜异位症的女性解释子宫内膜异位症在卵巢癌生存中的作用。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Contradicting results regarding ovarian cancer prognosis in women with endometriosis have been reported in the literature. Owing to the small sample size of previous studies, larger studies are required to elucidate the role of endometriosis in ovarian cancer prognosis. OBJECTIVE: This study aimed to evaluate the survival rate in women with ovarian cancer with or without histologically proven endometriosis in a Dutch population-based cohort. STUDY DESIGN: All women with ovarian cancer diagnosed between 1990 and 2015 were identified from the Netherlands Cancer Registry. We linked these women with the Dutch nationwide registry of histopathology and cytopathology (Pathologisch-Anatomisch Landelijk Geautomatiseerd Archief) to identify all women with histologically proven endometriosis. We compared the prognosis of patients with ovarian cancer with and without histologically proven endometriosis. Primary outcome was the overall survival with subgroup analyses stratified by histologic ovarian cancer subtype and stage. Multivariable Cox proportional hazard analysis was used to estimate hazard ratios with 95% confidence intervals. RESULTS: We included 32,419 patients with ovarian cancer, of whom 1979 (6.1%) had histologically proven endometriosis. The median age of histologic endometriosis diagnosis was 53 years (interquartile range, 46-62). Of all women with ovarian cancer and endometriosis, 81.2% received a diagnosis of synchronous endometriosis and ovarian cancer. The endometriosis cohort was younger at ovarian cancer diagnosis, had more favorable tumor characteristics, and more often had surgical treatment for ovarian cancer than the women without endometriosis. These variables were included in the multivariable model as confounders. Women with histologically proven endometriosis had a significantly better prognosis in both crude and adjusted analyses (hazard ratio, 0.46; 95% confidence interval, 0.43-0.49; P<.0005, and adjusted hazard ratio, 0.89; 95% confidence interval, 0.83-0.95; P<.05, respectively). CONCLUSION: Women with ovarian cancer and histologically proven endometriosis had longer overall survival than women with ovarian cancer without endometriosis, even after adjustment for confounders. Future studies on ovarian cancer treatment and prognosis should consider stratifying by endometriosis status to elucidate its role. Furthermore, women diagnosed as having ovarian cancer and concurrent endometriosis should be explained the role of endometriosis in ovarian cancer survival.

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Hermens M, van Altena AM, van der Aa M, et al. Ovarian cancer prognosis in women with endometriosis: a retrospective nationwide cohort study of 32,419 women. Am J Obstet Gynecol. 2020. PMID: 32841629. doi:10.1016/j.ajog.2020.08.056

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。